This mechanism has been confirmed in MCT-induced experimental models of PAH: pulmonary TGF-β signaling is markedly upregulated, whereas blocking TGF-β receptor type I to inhibit excessive SMAD2/3 activation significantly attenuates vascular remodeling. Here, SMAD2 is linked to pulmonary arterial hypertension.